E2 ModerateModerate confidencePEM ✗Machine draft
Metabolic Dysfunction in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Not Due to Anti-mitochondrial Antibodies.
Nilsson, Isabell, Palmer, Jeremy, Apostolou, Eirini et al. · Frontiers in medicine · 2020 · DOI
Quick Summary
Researchers tested whether ME/CFS patients have immune system antibodies that attack their mitochondria (the energy-producing parts of cells), similar to what happens in a different disease called primary biliary cholangitis. They found that ME/CFS patients almost never have these specific antibodies, while patients with the other disease have them consistently. This suggests that the energy problems seen in ME/CFS are caused by something other than the immune system attacking mitochondria.
Why It Matters
Previous research suggested ME/CFS involves energy metabolism problems similar to those in autoimmune diseases. This study clarifies that autoimmune antibodies are not the primary mechanism, redirecting research toward other explanations for the observed metabolic dysfunction. This helps researchers focus on non-antibody biological mechanisms that may underlie ME/CFS pathophysiology.
Observed Findings
- Only 1 of 161 ME/CFS patients tested positive for anti-PDC antibodies, compared to 15/15 PBC patients
- Anti-mitochondrial autoantibodies (inner and outer membrane) were negative across the ME/CFS cohort
- Anti-cardiolipin antibody levels in ME/CFS patients did not differ significantly from healthy blood donors
- No anti-PDC reactivity was detected in fibromyalgia (0/14), multiple sclerosis (0/29), or healthy control (0/44) groups
Inferred Conclusions
- Mitochondrial/metabolic dysfunction in ME/CFS cannot be explained by circulating autoantibodies against the tested mitochondrial epitopes
- The energy blockade mechanism in ME/CFS differs fundamentally from that in PBC and is not antibody-mediated
- Other serum factors or non-immune biological mechanisms likely underlie the metabolic dysfunction observed in ME/CFS
Remaining Questions
- What non-antibody serum factors or biological mechanisms are responsible for the observed mitochondrial dysfunction in ME/CFS?
- Are there other mitochondrial autoantigen targets not tested in this study that could be relevant to ME/CFS pathophysiology?
- Does the metabolic dysfunction in ME/CFS involve post-translational modifications or other mechanisms that bypass antibody-mediated pathways?
What This Study Does Not Prove
This study does not prove that mitochondrial dysfunction doesn't occur in ME/CFS—only that antibodies are not responsible for it. It also does not identify what actually causes the metabolic problems observed in ME/CFS patients. The cross-sectional design cannot establish causation or temporal relationships, and unmeasured serum factors or non-immune mechanisms could still drive disease.
Metadata
- DOI
- 10.3389/fmed.2020.00108
- PMID
- 32296708
- Review status
- Machine draft
- Evidence level
- Single-study or moderate support from human research
- Last updated
- 8 April 2026